Dissertation > Excellent graduate degree dissertation topics show

Application of Serum Proteomic Mass Spectra Analysis and Serum HER2 in Breast Cancer

Author: WuFan
Tutor: ChenQiang；YeYunBin
School: Fujian Medical
Course: Oncology
Keywords: Surface enhanced laser desorption ionization time-of-flight mass spectrometry Weak cation exchange chip Breast Cancer Proteomics Serum HER2
CLC: R737.9
Type: Master's thesis
Year: 2008
Downloads: 133
Quote: 0
Read: Download Dissertation

Abstract

Objective: surface enhanced laser desorption ionization time of flight mass spectrometry (SELDI-TOF-MS), technical analysis of healthy women, patients with benign breast tumor and breast cancer patient serum protein profiling, screening distinct proteins, and breast cancer serum protein spectrum model, and analyze the different stages, different lymph node metastasis, and serum protein profiling differences before and after surgery to explore the organization of breast cancer patients; analysis of the relationship between the organization HER2 in breast cancer patients with serum HER2 and HER2 status between the serum protein spectrum HER2 HER2 status with serum and serum protein spectrum correlation. METHODS: SELDI technology, weak cation exchange chip (CM10) binding to serum proteins, analysis of 113 cases of breast cancer patients, serum samples of 103 cases of benign breast tumor patients and 92 healthy controls were women, get their protein spectra using Biomarker Pattern Software analysis of three protein spectra and the initial establishment of the classification tree model, verified by blind sieve classification tree model. Further analysis of the different stages of breast cancer, lymph node metastasis, and before and after surgery protein spectral differences. Immunohistochemical detection of tissue HER2 expression, ELISA assay of serum HER2 level analysis of the tissue of patients with breast cancer, HER2 status and serum HER2, and serum protein spectrum. Results: breast cancer patients and healthy control females are more screened 12 statistically significant protein peaks, the combination of three protein peaks (4179,2740,2947 Da) were selected to build for the classification the Biomarker Pattern (BPS) software analysis tree model (model I). Benign breast tumor patients and healthy control women screened 11 statistically significant protein peaks, software analysis to elect two protein peaks (4179,6442 Da) to build the classification tree model (model II). Breast cancer patients with benign breast tumor patients screened two significant protein peaks, two protein peaks (7985 and 15952 Da) elected by the software to build the classification tree model (model III). Joint analysis of the three-group differences in serum protein spectrum protein peak 15952 Da in breast cancer and healthy control women, breast cancer and benign breast tumor comparison, a statistically significant difference (breast peak 12.00 ± 5.42, 6.13 ± 3.31 peak benign breast tumor healthy control women peak 6.08 ± 4.23), protein peak 7985 Da in breast cancer, benign breast tumor and healthy controls were statistically significant differences between the three groups of the women (breast peak 10.01 ± 3.75, benign breast tumor peak 6.09 ± 2.35 healthy control women peak 4.08 ± 2.27), the remaining 10 protein peaks in breast cancer and benign breast tumor comparison the difference was not statistically significant. I breast cancer and healthy control women have statistically significant differences in 10 protein peaks. Ⅳ stage Ⅰ - Ⅲ breast cancer patients found no statistically significant differences in protein peaks. Axillary lymph node negative with axillary lymph node-positive breast cancer between the comparison found no statistically significant differences in protein peak. 2947,3272,7985,15952 Da the four protein peak after a month peak trend change to the normal peak 7783 Da protein peaks in the seven days after surgery and after surgery were increased in January, protein peak 4179,5642, 6442,6639,8705,13771 Da 7 days after surgery and postoperative January were lower than the control peak levels. On ELISA assay serum HER2-positive rate and tissue HER2 status related organizations HER2-positive breast cancer serum HER2-positive rate is higher than the organization HER2-negative breast cancer, some of these bodies HER2-negative breast cancer increased serum HER2. The SELDI technology analysis organization HER2-positive and-negative breast cancer serum proteomic spectra and found no significant differences between protein peaks. Conclusion: (1) the use of SELDI-TOF-MS technology can filter out breast cancer, benign breast tumor and healthy controls the female serum protein spectrum differences in protein peak, peak changes in protein peak 7985 Da healthy women may be able to identify benign breast tumor protein peak of 15952 Da and breast cancer, may identify breast cancer and non-breast cancer serum markers. (2) breast cancer patients before surgery, after seven days, and after January serum protein profiling differences, changes in the protein peaks 2947,3272,7985,15952 Da peak may be used for metastasis and recurrence monitoring. (3) serum HER2-positive rate and tissue HER2 expression status tissue HER2-positive breast cancer serum HER2-positive rate is higher than the organization HER2-negative breast cancer, and some of the tissue HER2-negative breast cancer increased serum HER2. (4) have not yet found differential expression of tissue HER2-positive and-negative breast cancer patients, serum protein spectrum.

Application of Serum Proteomic Mass Spectra Analysis and Serum HER2 in Breast Cancer

Abstract

Related Dissertations